Loading...
•
Dec 31, 2025
Bioventus Q4 2025 Earnings Report
Bioventus reported modest revenue growth with strong profitability improvement and cash generation in Q4 2025.
Key Takeaways
Bioventus delivered Q4 revenue growth with strong organic expansion and improved profitability. Net income turned positive year over year and adjusted EBITDA increased significantly, supported by strong demand in Pain Treatments and disciplined cost management.
Revenue reached $157.9M, up 2.8% reported and 10.0% organic growth.
Net income attributable to Bioventus improved to $14.8M from a prior-year net loss.
Adjusted EBITDA increased 30% year-over-year to $36.7M driven by higher margins and operating leverage.
Strong demand in Pain Treatments drove double-digit growth while Restorative Therapies declined due to the Advanced Rehabilitation divestiture.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Bioventus expects continued growth and profitability expansion in 2026 supported by portfolio demand and improved cash generation.
Positive Outlook
- Expected net sales growth to $600M–$610M (~6–7% growth).
- Adjusted EPS forecast of $0.73–$0.77 indicating earnings expansion.
- Projected cash from operations of $82M–$87M.
- Continued above-market growth expected across core product portfolio.
- Operating leverage and margin expansion anticipated.
Challenges Ahead
- GAAP earnings guidance not provided due to uncertainty around adjustments.
- Business exposed to regulatory risks including FDA classification changes.
- Potential tariff or trade policy changes could impact international operations.
- Dependence on a limited number of key products for growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...